BiotechMashup

by Pierre-Henri Puech, Damien Nevoltris, Philippe Robert, Laurent Limozin, Claude Boyer, Pierre Bongrand

by Pierre-Henri Puech, Damien Nevoltris, Philippe Robert, Laurent Limozin, Claude Boyer, Pierre Bongrand

Using newer vaccine platforms which have been effective against malaria in rodent models, we tested five immunization regimens against Plasmodium knowlesi in rhesus monkeys. All vaccines included the same four P. knowlesi antigens: the pre-erythrocytic antigens CSP, SSP2, and erythrocytic antigens AMA1, MSP1.

by Elisa Nurzia, Daniele Narzi, Alberto Cauli, Alessandro Mathieu, Valentina Tedeschi, Silvana Caristi, Rosa Sorrentino, Rainer A. Böckmann, Maria Teresa Fiorillo

Monkeys infected with an emerging malaria strain are providing a reservoir for human disease in Southeast Asia, according to new research. The study confirms that the species has not yet adapted to humans and that monkeys are the main source of infection.

A Plasmodium falciparum 3D7 strain Apical Membrane Antigen-1 (AMA1) vaccine, formulated with AS02A adjuvant, slowed parasite growth in a recent Phase 1/2a trial, however sterile protection was not observed. We tested this AS02A, and a Montanide ISA720 (ISA) formulation of 3D7 AMA1 in Aotus monkeys.

Neutralizing antibodies have been shown to protect macaques against SHIV challenge. However, genetically diverse HIV-1 clades have evolved, and a key question left unanswered is whether neutralizing antibodies can confer cross-clade protection in vivo.

Neutralizing antibodies have been shown to protect macaques against SHIV challenge. However, genetically diverse HIV-1 clades have evolved, and a key question left unanswered is whether neutralizing antibodies can confer cross-clade protection in vivo.

Two new studies provide a significant advance in understanding how some species of monkeys such as sooty mangabeys and African green monkeys avoid AIDS when infected with SIV, the simian equivalent of HIV.